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The outcome of radiotherapy can be further improved by combining radiotherapy with nanoparticles.
Previous biological studies showed a signiﬁcant ampliﬁcation of the biological damage in cells charged
with nanoparticles prior to radiotherapy treatments. The rationale has been based on the physical dose
enhancement. However, this subject is still a matter of controversy and there are clear indications that
biochemical eﬀects may play a key role in the radiosensitization eﬀects of nanoparticles. Within this
context, the main goal of our study was to provide new insights into the radiosensitization eﬀects of
F98 glioma cells exposed to gadolinium nanoparticles combined with clinical megavoltage beams, and
compare them with respect to kilovoltage radiotherapy (commonly used in combination with nano-
particles). For this purpose, we used synchrotron-based Fourier transform infrared microspectroscopy
(SR-FTIRM) to provide relevant information on the treatment-induced biochemical changes of the main
cell biomolecules. Biochemical diﬀerences were evaluated after the treatments to assess cellular damage.
Multivariate analysis revealed nanoparticle-dependent changes in megavoltage treated cells. The main
spectral variations were related to conformational changes in the protein secondary structures, which
might be induced by radiation damage and by changes or rearrangements in the nucleic acid structures
due to the initiation of DNA repair mechanisms. We also observed signiﬁcant changes in the phosphate I
and II bands, which concerns DNA damage, while few changes were detected in the lipid region.
Spectroscopic data showed that these changes increased as a function of the dose. Finally, PCA analysis
did not discriminate clearly between megavoltage and kilovoltage groups treated with nanoparticles, indi-
cating that megavoltage radiosensitization eﬀects might not diﬀer signiﬁcantly from those in kilovoltage
radiotherapy.
1 Introduction
The use of nanoparticles (NP) as tumour radiosensitizers was
proposed by Hainfeld and collaborators in 2004, when they
first reported the control of a malignant tumour (EMT-6)
in vivo through the preferential absorption of X-rays by 1.9 nm
Au NP.1 This pioneering experiment, along with the results
obtained in subsequent biological studies (see ref. 2–7, among
others), boosted the use of NP as a promising strategy to
increase the eﬃciency of radiotherapy.
The basis for NP use is their selective accumulation within
tumours due to the enhanced permeability and retention
(EPR) eﬀect,8 leading to a higher cell penetration and less
adverse eﬀects with respect to conventional radiosensitizers.9
Therefore, the goal of combining NP with radiotherapy is to
improve tumour cell killing, and thus, the diﬀerential eﬀect
between healthy and tumour tissues. An increase in the radio-
sensitivity of tumour cells treated with NP has been observed
in vitro and in vivo, using kilovoltage and also megavoltage
photon beams.10–12
The biological findings have been basically described in
terms of physics since the presence of (high-Z) NP increases
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the probability of photoelectric and Compton interactions
(and, thus, the generation of short-range secondary elec-
trons).13 This results in a local dose enhancement in the
tumour. However, the radiosensitization observed in some
biological experiments is greater than the predicted increase
in the physical dose,14–16 indicating that the biological
response may not be driven only by dose enhancement
(physical) eﬀects. Other mechanisms such as the production
of reactive oxygen species (ROS) and oxidative stress, DNA
damage induction, cell cycle eﬀects and potential inter-
ference with the bystander eﬀects may play a major
role.6,14–19 These mechanisms might be amplified in combi-
nation with radiotherapy, and thus increase the anticancer
eﬃcacy of NP. In addition, diﬀerent radiosensitizing eﬀects
are expected according to the NP size, type, chemical nature,
concentration, intracellular localization, radiotherapy con-
figuration (energy) and cell line used.17 That is why the bio-
logical mechanisms of nanoparticle radiosensitization still
remain unknown.
Within this context, the objective of this study is to use syn-
chrotron-based Fourier transform infrared microspectroscopy
(SR-FTIRM) to disentangle radiosensitization eﬀects in the
F98 glioma rat cell line treated with GdNP (AGuIX®) combined
with radiotherapy. In addition to its radiosensitization pro-
perties, the use of Gd and its chemical derivatives is particu-
larly interesting since it is the most widely used contrast agent
for magnetic resonance imaging (MRI); this makes Gd a
perfect tool for theragnosis (providing imaging and therapy at
the same time).20 Thanks to this dual capacity, the use of
GdNP is increasing.
FTIRM is a vibrational technique for the biochemical
analysis of cells on a microscopic scale. FTIRM methods
have been used to study the cell cycle, apoptosis, diﬀeren-
tiation, and proliferation of diﬀerent cell lines and tissues
(see, for instance ref. 21–24). Analysis of the infrared spectra
provides relevant information on the treatment-induced bio-
chemical modifications of the main cell biomolecules
(nucleic acids, proteins and lipids). In our previous work,25
we studied the biochemical structure alterations of bio-
molecules inside cells induced by low energy X-ray
irradiations and GdNP using FTIRM. In particular, we
observed important spectral signature alterations in the fin-
gerprint (DNA and protein) and lipid regions related to
changes in the cellular function and cell death processes.
The main goal of the present study is to use SR-FTIRM to
gain new insights into the radiosensitization eﬀects involved
when using GdNP at megavoltage (MV) photon energies
(normally used in clinics) with respect to kilovoltage (kV)
photons (commonly used in combination with NP). To the
best of our knowledge, this is the first study that uses syn-
chrotron-based FTIRM to evaluate NP-based radiotherapy
approaches. The biochemical information provided by the
highly brilliant infrared light source produced at ALBA
Synchrotron leads to a clear advantage in spectral quality at
a cellular level and will allow better characterization of NP-
induced damage in cells.
2 Materials and methods
2.1 F98 cells and cell culture
The F98 rat glioma cell line (ATCC-CRL-2397) was purchased
from LGC Standards (Molsheim, France). This type of cell has
a highly invasive growth pattern and is weakly immunogenic
in syngeneic Fischer rats.26
The cells were cultured in high glucose DMEM medium
(Gibco) supplemented with 10% fetal calf serum, 1% penicil-
lin–streptomycin (10 000 units per mL each), 2 mM
L-glutamine, 1 mM sodium pyruvate and 10 mM HEPES in an
incubator at 37 °C. The cells were seeded in 6-well plates on
the day prior to the irradiation; 2 mL of a 5 × 104 cells per mL
suspension were placed in each well and incubated overnight
in order to reach a 75% confluence rate on the day of
irradiation.
2.2 Nanoparticles
Gadolinium NP (AGuIX®; Activation and Guiding of
Irradiation by X-ray) were purchased from Nano-H (Lyon,
France). These nanoparticles consist of a polysiloxane network
surrounded by around 10 gadolinium chelates (diethyl-
enetriaminepentaacetic acid, DTPA) covalently grafted to the
polysiloxane inorganic matrix. The nanoparticles present a dia-
meter of 3.0 ± 1.0 nm.27 The eﬀectiveness of the AGuIX® NP
has been proved in previous biological studies with several
types of cell lines or animal models, and irradiation
conditions.28–30
A nanoparticle stock solution of 100 mM was obtained by
solubilization in ultrapure Millipore (DirectQ 8) water and kept
at 4 °C. For cell treatment, 3 mL of 1 mM nanoparticle solution
in fresh supplemented medium was added into the wells and
incubated for 6 hours at 37 °C. At such concentrations, NP are
not toxic.9,31 A recent study with the same type of NP and cell
line showed that the uptake of GdNP was time-dependent and
reached a plateau after a 5-hour incubation time.19
2.3 Irradiation
Kilovoltage and megavoltage irradiations were performed at
the Hospital Universitari Sant Joan de Reus. Kilovoltage
irradiations were performed with a Gulmay D3300 kilovoltage
X-ray therapy unit (Gulmay Ltd, Byfleet, UK) with an accelerat-
ing potential voltage of 60 kV (HVL = 1.19 mm Al). Dose con-
formation was performed with a circular 4 cm-diameter cone
at 30 cm from the source. The cells were irradiated at a dose
rate of 2.1 Gy min−1. Megavoltage irradiations were performed
using a 6 MV photon beam from a Varian 2100 linear accelera-
tor (Varian Medical System, Palo Alto, USA). The dose rate at
the cells was also 2.1 Gy min−1 at a source to surface distance
(SSD) of 95 cm and at 5 cm-depth (cell location). In both cases,
several irradiation doses were delivered to the cells: 0 Gy (no
irradiation), 5, 10 and 20 Gy.
2.4 SR-FTIRM sample preparation
SR-FTIRM sample preparation was performed following our
previous protocol.25 In order to evaluate immediate treatment-
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induced eﬀects, the cells were fixed two hours after the
irradiation. For this purpose, the medium was removed
(having previously collected floating cells) and 100 μL of a
0.05% trypsin–EDTA solution (Lonza) was added to each well
in order to detach the cells; the floating cells were added back
to the trypsinised cells to take into account the whole cell
population that was treated. Then, 500 μL of supplemented
DMEM medium was added and the cell suspension was centri-
fuged at 1500 rpm for 5 minutes at 4 °C. The cellular pellet
was rinsed with PBS, and re-centrifuged at 1500 rpm for
5 minutes. The pellet was then re-suspended in 10% formalin
neutral buﬀered solution (Sigma-Aldrich) and incubated for
1 hour at room temperature. Then, the samples were centri-
fuged at 1500 rpm for 5 minutes, and the pellet was rinsed 3
times in Millipore water to wash out the residual phosphate
ions. Dried cells, previously deposited on 0.5 mm-thick infra-
red transparent calcium fluoride (CaF2), were then analyzed by
SR-FTIRM.
2.5 SR-FTIRM measurements
SR-FTIRM measurements (transmission mode) were per-
formed at the MIRAS beamline of ALBA Synchrotron using a
Hyperion 3000 microscope coupled to a Vertex 70 spectrometer
(Bruker, Germany). The FTIR microscope is supplied with a
liquid nitrogen-cooled mercury cadmium telluride 50 μm MCT
detector. This microscope operates with a 36× Schwarzschild
magnification objective (NA = 0.65) coupled to a 36× magnifi-
cation condenser. All spectra were obtained using a single
masking aperture size of 7 μm × 7 μm, covering the full cell
size. Single point maps of individual spectra were collected in
the 3800–900 cm−1 mid-infrared range at 4 cm−1 resolution
with 256 co-added scans per spectrum. For each condition,
between 60 and 80 cells were randomly collected. A back-
ground measurement was performed under the same acqui-
sition parameters every 10 samples.
2.6 SR-FTIRM data treatment and statistical analysis
Spectral features to assess the diﬀerences between the control
and treated cells were highlighted by Principal Component
Analysis (PCA) using Unscrambler X (CAMO Software AS,
Norway). PCA was performed on vector normalized second
derivative spectra (11 smoothing points, Savitzky–Golay algor-
ithm). Vector normalization and PCA were applied in the
3000–2800 & 1760–950 cm−1 spectral regions, as performed in
previous FTIRM studies.21,32
Raw spectra were corrected in the 3100–950 cm−1 spectral
region following the rubber band method (32 baseline points)
using OPUS 7.5 (Bruker Optik GmbH, Germany). Then, the
area of the following bands/regions was evaluated: methylene
asymmetric stretching, 2945–2900 cm−1 (CH2); methyl asym-
metric stretching, 2980–2945 cm−1 (CH3); lipid spectral region,
3000–2835 cm−1 (Lip); amide I, 1710–1598 cm−1 (AI); amide II,
1590–1483 cm−1 (AII); phosphate I, 1270–1186 cm−1 (PhI); and
phosphate II, 1146–1004 cm−1 (PhII). The total area
(3000–2835 and 1760–950 cm−1 regions) was associated with
the total cell biomass (Cell) following previous studies.32,33
Violin plots showing the probability density of the data for
diﬀerent ratios (PhI/AII, PhII/AII, AII/AI, Lip/Cell, CH2/Cell,
and CH2/CH3) were generated for the diﬀerent configurations.
These ratios have been reported to provide valuable infor-
mation on cell response after treatments.32,34
3 Results and discussion
Details of the SR-FTIRM analysis are presented in this section
for several irradiation modalities (megavoltage and kilovol-
tage), for several doses (from 0 to 20 Gy), and in the presence
(+NP) and absence (−NP) of GdNP. Section 3.1 shows the
eﬀects of GdNP at 0 Gy (without irradiation), while megavol-
tage radiotherapy results are presented in section 3.2. In
section 3.3, megavoltage radiosensitization eﬀects by GdNP are
compared with respect to kilovoltage radiation energies.
3.1 Radiosensitization eﬀects of GdNP
The eﬀects of the nanoparticles at 0 Gy (without irradiation)
are evaluated in this section. Fig. 1 shows the score plots (left)
and the loading plots (right) in the presence (+NP) and
absence (−NP) of nanoparticles in the 3000–2800 &
1760–950 cm−1 spectral regions. In the PCA score plot, each
single point represents a cell spectrum. The PCA plot shows
clusters of samples based on their similarity, while the loading
plot expresses the influence of the variables (wavenumbers) in
each principal component.
The PC1–PC2 score plot shows the separation in the two clus-
ters (−NP and +NP groups) with some overlapping. The group
separation is mostly along PC-1, which explains 41% of the var-
iance. The loading plot indicates that the largest biochemical
changes induced by the NP are associated with protein modifi-
cations in the region 1700–1500 cm−1. These results indicate
changes in the protein conformational structures (amide I and
amide II) from α-helix toward β-sheet.25,34,35
Fig. 2 and 3 show the second derivative for the two controls
(−NP and +NP) and the distribution of the relative intensities
of several spectral bands (Lip/Cell, PhI/AII and PhII/AII)
described in section 2.6, respectively. We observe changes in
the phosphodiester vibrations of the DNA. In particular, a shift
in the PO2
− asymmetric band (1238 cm−1) is detected in the
presence of NP. We also observe a decrease in the ratio of PhII/
AII in the NP-treated cells. These findings are in agreement
with the ones obtained in our previous work, which was
carried out with an internal source of infrared radiation.25
Protein and DNA modifications could be due to the biologi-
cal interactions of NP within the cells. Previous studies have
shown that NP can induce conformational changes in cell
proteins.36–38 Moreover, Taupin et al. reported proliferation
arrest and cell cycle modifications when using similar NP to
those used in our work.19 Thus, these FTIRM spectra changes
could also be related to initial modifications in the cells
induced by the NP.39,40
No significant diﬀerences were observed in the lipid region
in the PCA scores. However, the violin plots show a slight
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increase in the total lipid content (Lip/Cell ratio) for the popu-
lation of NP-treated cells. It is important to note that the cells
were fixed two hours after the irradiation to assess direct treat-
ment-induced eﬀects and that important lipid modifications
are typically detected at longer times after the treatment.19,25
3.2 Radiosensitization eﬀects of GdNP at megavoltage
radiation energies
Fig. 4 and 5 show the overall changes in the averaged absor-
bance spectra and the corresponding Savitzky–Golay second
derivative for several investigated groups, respectively. PCA
scores and loadings are shown in Fig. 6, which illustrates
sample grouping for the control and cells treated with mega-
voltage radiotherapy with/without GdNP for several doses
(5, 10 and 20 Gy) in the 3000–2800 & 1760–950 cm−1 spectral
regions. After the treatments (MV and/or NP), several infrared
Fig. 1 Eﬀect of the nanoparticles at 0 Gy (without irradiation). The PCA scores (left) and loading plots (right) are presented. ‘+NP’ labels the pres-
ence of nanoparticles and ‘−NP’ the absence of nanoparticles.
Fig. 2 Eﬀect of the nanoparticles at 0 Gy (without irradiation). The
Savitzky–Golay second derivative of the averaged absorbance spectra is
shown for the two controls. ‘+NP’ labels the presence of nanoparticles
and ‘−NP’ the absence of nanoparticles.
Fig. 3 Eﬀect of the nanoparticles at 0 Gy (without irradiation). The violin
plot shows the distribution of the relative intensities of several spectral band
ratios (Lip/Cell, PhI/AII and PhII/AII) described in section 2.6. ‘+NP’ labels
the presence of nanoparticles and ‘−NP’ the absence of nanoparticles.
Fig. 4 Averaged absorbance spectra for controls, megavoltage (MV)
and kilovoltage (kV) radiotherapy (10 Gy). ‘+NP’ labels the presence of
nanoparticles and ‘−NP’ the absence of nanoparticles. For clarity, the
diﬀerent averaged absorbance spectra have been shifted along the
absorbance axis.
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bands (mostly located in the protein and DNA regions) showed
intensity changes or frequency shifts.
The PCA scores do not discriminate clearly among the three
treated groups (+NP, MV −NP, and MV + NP) for 5 Gy.
Discrimination between the treated and control (−NP) groups
is mainly associated with PC-1 and, in particular, with changes
in the protein spectral region in the range 1700–1500 cm−1
(amide I and amide II). The separation increases in the pres-
ence of nanoparticles, as the MV + NP groups are clearly separ-
ated from the other treated groups, especially for 10 Gy and
20 Gy. The separation of the PCA scores for treated cells
increases as a function of the dose. The shift in amide I in the
treated cells with respect to the control is clearly seen in the
Savitzky–Golay second derivative plot (see the inset in Fig. 5).
This shift in amide I indicates a change in the overall con-
formational state in the secondary structure of proteins. In par-
ticular, it might be related to an increase in the amount of
β-sheet secondary structures, which is typically associated with
unfolding and/or denaturation of proteins or apoptosis.35,39
Immediately after the radiotherapy treatments, this protein
damage might be related to direct damage of the ionizing
radiation,41–44 and specifically to changes in the protein sec-
ondary structures due to changes or rearrangements in the
DNA structure.34,45 Moreover, in the violin plots of Fig. 7
(middle), we observed a slight increase in the absorbance
intensity of proteins (amide II) for the MV-treated cells with
respect to controls, as in previous studies.34 This might indi-
cate that the DNA repairing processes had started since they
normally involve a large quantity of enzymes which recognize
and correct physical damage in DNA.46
In the second derivative plot (Fig. 5), we can observe signifi-
cant changes between the ‘MV + NP’ and ‘MV − NP’ groups in
the DNA signatures in the region 1330–950 cm−1. Several
changes are found simultaneously (changes in the intensity
and shifts), which implies a number of diﬀerent variations in
the DNA organization. The most clear changes appear in the
vibrations of the phosphodiester groups; there are modifi-
cations in the PO2
− asymmetric band (1238 cm−1), especially
in the case of NP-treated cells. These modifications might be
associated with local conformational changes in the DNA,47,48
such as the formation of pyrimidine dimers or DNA–DNA and
DNA–protein cross-links.48 There is also a shift in the PO2
−
symmetric stretching (around 1085−1) in the NP-treated cells.
We also observed treatment-dependent absorbance variations
in the phosphate II band, as it can be seen in the (top right)
violin plots of Fig. 7. Taken together, these features could
point to an increase in DNA strand breaks, base cleavage reac-
tions and chromatin fragmentation34,45,48–51 for cells charged
with nanoparticles prior to MV radiotherapy irradiations.
An analysis of the PCA loading plots reveals less contri-
bution from the lipid region (3000–2800 cm−1). We observe a
slight increase in the total quantity of lipids for the treated
cells in Fig. 7 (bottom right). This is due to a slight increase in
the absorbance in the CH2 and CH3 stretching modes in the
treated cells (especially in the NP-treated group), indicating
some changes following lipid peroxidation or changed lipid
metabolism due to initial cell death processes.52,53 We do not
observe a significant increase in the ratio of CH2/CH3, which is
normally observed several hours after the treatment due to oxi-
dative processes occurring in response to treatment and con-
sistent with cell death.54,55
Finally, it is important to note that there is a clear increase
in the variance of the biochemical content of the cell popu-
lation after both treatments (nanoparticle and radiation), as
can be seen in Fig. 7, probably as a result of the initiation of
several DNA repair processes or cell death.50,56
3.3 Comparison of the megavoltage radiosensitization eﬀects
of GdNP with respect to kilovoltage radiation energies
PCA scores and loadings are shown in Fig. 8 for cells treated
with megavoltage and kilovoltage radiotherapy with/without
GdNP for several doses (5, 10 and 20 Gy) in the 3000–2800 &
1760–950 cm−1 spectral regions.
PCA does not show significant diﬀerences between the MV
and kV groups in the absence of NP. Moreover, in the presence
of nanoparticles, both the ‘kV + NP’ and ‘MV + NP’ groups are
equally separated (along PC-1) from the ‘−NP’ groups.
Discrimination of NP-treated groups is mainly associated with
PC-1 and, in particular, with changes in the protein spectral
region (amide I and amide II). As has been discussed in the
previous section, these spectral variations may be related to
conformational changes of the protein secondary structures
due to radiation damage or due to initial changes or rearrange-
ments in the nucleic acid structures. We do not observe signifi-
cant changes in the content of proteins (amide II) between
megavoltage and kilovoltage groups (see Fig. 7, middle), which
has been previously related to DNA repair mechanisms.46,48
The results presented here indicate that similar damage
occurs in the F98 glioma cells for both types of irradiation (MV
and kV) since PCA analysis does not allow clear discrimination
between the two ‘+NP’ groups. However, in the Savitzky–Golay
Fig. 5 Savitzky–Golay second derivative of the averaged absorbance
spectra for controls, megavoltage (MV) and kilovoltage (kV) radiotherapy
(10 Gy). The insets show a zoom of the 1700–1600 and 1300–1000 cm−1
regions. ‘+NP’ labels the presence of nanoparticles and ‘−NP’ the absence
of nanoparticles.
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Fig. 6 Radiosensitization eﬀects of GdNP at megavoltage (MV) radiation energies for several doses (5, 10 and 20 Gy). The PCA scores (left) and
loading plots (right) are presented. ‘+NP’ labels the presence of nanoparticles and ‘−NP’ the absence of nanoparticles.
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second derivative plot (Fig. 5) and the DNA-related violin plots
(Fig. 7, top), we can observe some diﬀerences in the phosphate
I and II infrared bands (1270–1186 cm−1 and 1146–1004 cm−1,
respectively). On average, there is a decrease in the intensities
of these bands in the ‘kV + NP’ group with respect to the ‘MV +
NP’ group, which may indicate some diﬀerences in DNA
damage in both treatments.
Our SR-FTIRM analysis, supported by multivariate analysis,
shows clear radiosensitization eﬀects for megavoltage radio-
therapy, which do not diﬀer significantly from the ones
observed in kilovoltage radiotherapy. Despite Monte Carlo
simulations at the nanoscale predicting that dose enhance-
ment should be much higher using kV energies (compared to
MV beams),57 previous biological studies have observed signifi-
cant radiosensitization in studies where no dose enhancement
was expected.14 Butterworth et al. has reported that for most of
the experimental results, the observed enhancement is higher
than the overall physical dose increase.14 Our results, in agree-
ment with these observations, indicated that the biochemical
component in the nanoparticle radiosensitization plays a
major role.
4 Conclusions
This synchrotron-based infrared microspectroscopy investi-
gation showed infrared spectral modifications in F98 cells
exposed to Gd nanoparticles combined with megavoltage (nor-
mally used clinically) and kilovoltage radiotherapy (commonly
used in combination with nanoparticles). Biochemical diﬀer-
ences were evaluated two hours after the irradiation to assess
cellular damage.
Fig. 7 Violin plots showing the distribution of the relative intensities of several spectral bands (PhI/AII, PhII/AII, AII/AI, Lip/Cell, CH2/Cell and CH2/
CH3 scaled by a factor 5) for controls, megavoltage (MV) and kilovoltage (kV) radiotherapy. The speciﬁc intervals for each ratio are described in
section 2.6.32 For clarity, one dose (10 Gy) is presented. ‘+NP’ labels the presence of nanoparticles and ‘−NP’ the absence of nanoparticles.
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Fig. 8 Radiosensitization eﬀects of GdNP at megavoltage (MV) and kilovoltage (kV) radiation energies for several doses (5, 10 and 20 Gy). The PCA
scores (left) and loading plots (right) are presented. ‘+NP’ labels the presence of nanoparticles and ‘−NP’ the absence of nanoparticles.
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PCA results showed NP-dependent changes in megavoltage
treated cells. The main spectral variations were related to con-
formational changes of the protein secondary structures
(amide I and amide II), which were probably related to radi-
ation damage and to changes or rearrangements in the nucleic
acid structures due to the initiation of DNA repair mecha-
nisms. We also observed significant changes in the phosphate
I and II bands (1270–1186 cm−1 and 1146–1004 cm−1, respect-
ively), while minimal changes were observed in the lipids
region. Spectroscopic data showed that these changes
increased as a function of the dose, especially at 10 and 20 Gy.
PCA analysis did not discriminate clearly between megavol-
tage and kilovoltage groups in the presence of nanoparticles,
indicating that GdNP radiosensitization eﬀects in megavoltage
radiotherapy do not diﬀer significantly from those in kilovol-
tage radiotherapy. We observed some diﬀerences between the
two types of radiation in the average intensities of the phos-
phate I and II bands, which might indicate higher DNA
damage in kilovoltage irradiation. However, few diﬀerences
were observed in the protein region.
Finally, it is important to note that it is diﬃcult to draw
overall conclusions for other types of nanoparticles or cell
lines, since radiosensitization eﬀects depend on the nano-
particle size and type, surface functionalization, concentration
and intracellular localization, cell type and irradiation con-
figuration. Thus, further work is required to shed more light
on the mechanisms involved in the radiosensitization eﬀects
of nanoparticles. Comprehensive characterization studies of
diﬀerent cellular responses to GdNP are required for the
further development of this promising technique.
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